The Portnoy Law Firm has initiated a securities class action lawsuit targeting Ultragenyx Pharmaceutical on behalf of investors who purchased company securities during a 29-month period spanning from August 3, 2023 through December 26, 2025. The complaint alleges that the biopharmaceutical company disseminated false and misleading statements to the market regarding its investigational drug setrusumab and related Phase III clinical trial data.
At the center of the allegations are claims that Ultragenyx failed to adequately disclose material risks associated with interim analysis benchmarks for the Orbit study and methodological limitations from Phase II trials, specifically the absence of placebo-controlled comparisons. According to the lawsuit, these omissions represented significant gaps in information that should have been communicated to investors evaluating the company's pipeline and financial prospects.
The class action seeks to represent all investors who suffered losses during the specified period. The lawsuit highlights how undisclosed trial design considerations and risk factors may have materially affected investor decision-making and the company's stock valuation. Ultragenyx has not yet issued a public response to the legal action.